北京若生智能科技有限公司
Drug Database
SA

salbutamol + ipratropium bromide (Respimat Combivent)

✓ Approved

Boehringer Ingelheim International GmbH · ADRB2 · 小分子

什么是 salbutamol + ipratropium bromide？

salbutamol + ipratropium bromide 是一种小分子，由Boehringer Ingelheim International GmbH研发。该药已获批，用于治疗相关适应症，给药途径：Inhaled。

药物档案

商品名Respimat Combivent
公司Boehringer Ingelheim International GmbH
药物类别小分子
分子靶点ADRB2, CHRM1, CHRM2, CHRM3, CHRM4
给药途径Inhaled
状态Approved
来源： ClinicalTrials.gov, Boehringer Ingelheim International GmbH

作用机制

分子靶点

salbutamol + ipratropium bromide 作用于 5 个分子靶点：

ADRB2adrenoceptor beta 2 (B2AR, ARB2)
CHRM1cholinergic receptor muscarinic 1 (M1, HM1)
CHRM2cholinergic receptor muscarinic 2 (HM2)
CHRM3cholinergic receptor muscarinic 3 (HM3, PBS)
CHRM4cholinergic receptor muscarinic 4 (HM4, M4R)
需要更深入的分析？Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

salbutamol + ipratropium bromide 针对 2 个适应症，涉及 1 个治疗领域。

治疗领域疾病/病症分期
Respiratory, thoracic and mediastinal disordersChronic obstructive pulmonary disease✓ Approved
Respiratory, thoracic and mediastinal disordersAsthmaPhase III

相关研究文献

PubMedNano letters2026-09-09

Lewis Acid-Driven Perovskite Quantum Dot Surface Reconstruction for Deep-Blue LEDs Approaching the Rec. 2020 Standard.

Chen Yanfeng Y, Yang Bing B, Zhang Erdong E, Chen Nian-Ke NK et al.

Perovskite quantum dot light-emitting diodes (PQD LEDs) are promising candidates for high-color-gamut displays, yet deep-blue devices meeting the Rec. 2020 standard with high efficiency and stability remain a tremendous challenge. Here we present a Lewis acid-driven surface reconstruction strategy to enable high-performance deep-blue CsPbBr3 PQD LEDs. Strong ionic interactions between Sr2+ and octanoic acid promote octylamine protonation, triggering simultaneous PQD size reduction, defect suppression, and photoluminescence quantum yield (PLQY) enhancement. The reconstructed PQDs exhibit deep-blue emission at 461 nm with a narrow 18 nm full width at half-maximum and a PLQY of 80%. The resulting LEDs deliver 98.1% color purity, color coordinates of (0.146, 0.059), and full compliance with Rec. 2020 blue specifications. A peak external quantum efficiency of 8.5% and an operational half-lifetime of 41 min are achieved, among the highest reported for pure-bromide deep-blue PQD LEDs. This work provides a facile surface-engineering strategy for efficient deep-blue optoelectronics.

PMID 42715066
阅读全文 →
PubMedACS applied materials & interfaces2026-09-09

Gallic Acid-Crosslinked EmimBr/AA Ionogels Derived from a Polymerizable Deep Eutectic Solvent toward Intelligent Human-Machine Interfaces.

Cao Mengmeng M, Li Nan N, Ji Xingxiang X, Chen Wei W

Flexible ionogels are promising candidates for next-generation human-machine interfaces; however, achieving a balanced combination of mechanical robustness, optical transparency, ionic conductivity, and environmental stability remains a persistent challenge. Herein, we report a multifunctional ionogel derived from a polymerizable deep eutectic solvent (PDES) composed of 1-ethyl-3-methylimidazolium bromide and acrylic acid (EmimBr/AA), in which gallic acid (GA) is introduced as a multivalent hydrogen-bond donor and dynamic physical crosslinking hub, thereby eliminating the need for additional chemical crosslinkers. Benefiting from the synergistic effects of the PDES matrix and GA-mediated molecular-scale interactions, the resulting poly(EmimBr/AA/GA) ionogels exhibit a well-balanced set of properties, including a tensile strength of 0.84 MPa, an elongation at break of 1556%, high optical transparency (>92%), an ionic conductivity of 4.4 × 10-3 S m-1, and strong interfacial adhesion (54 kPa on copper). In addition, the reversible dynamic interactions endow the ionogels with intrinsic self-healing capability (91.2% healing efficiency after 4 h at 100 °C) and recyclability. As proof-of-concept applications, the ionogels were successfully integrated into skin-attachable strain sensors, a 4 × 4 tactile array, and a customized convolutional neural network-assisted smart glove, achieving classification accuracies of 98.5% for 10-class fine hand gestures and 99.08% for 5-class macroscopic body motions. This work offers a general strategy for constructing sustainable, crosslinker-free, high-performance ionogels for intelligent wearable electronics and advanced human-machine interfaces.

PMID 42715440
阅读全文 →
PubMedBiological & pharmaceutical bulletin2026-09-09

Realgar Transforming Solution Triggers Ferroptosis-Associated Death in NB4 Leukemia Cells through Disruption of Iron Homeostasis and Suppression of the SLC7A11/GPX4 Axis.

Yue Zhaorong Z, Liu Qinghong Q, Wang Yanni Y, Wang Ruyue R et al.

Realgar (As4S4) has long been used in traditional medicine, yet its clinical application remains limited due to poor bioavailability and toxicity. Realgar transforming solution (RTS), a bioleached product generated through microbial transformation of realgar, exhibits enhanced anti-tumor activity; however, its underlying mechanism remains unclear. This study investigated whether ferroptosis contributes to the anti-leukemic effects of RTS in NB4 cells, focusing on iron homeostasis and the solute carrier family 7 member 11 (SLC7A11)/glutathione peroxidase 4 (GPX4) antioxidant axis. NB4 cells were treated with RTS, arsenic trioxide (ATO), or realgar, and cell viability was assessed by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay. Transcriptomic profiling, biochemical assays, fluorescence probes, flow cytometry, and Western blotting were employed to evaluate ferroptosis-related changes. RTS inhibited NB4 cell viability more effectively than ATO or realgar at comparable arsenic concentrations. Transcriptomic analysis indicated significant enrichment of ferroptosis-related pathways. RTS decreased glutathione and superoxide dismutase levels, increased malondialdehyde accumulation and lipid peroxidation, disrupted mitochondrial membrane potential, and elevated intracellular total iron and mitochondrial Fe2+ levels. Additionally, RTS downregulated SLC7A11 and GPX4 and altered the expression of iron metabolism-related proteins, including transferrin receptor protein 1, nuclear receptor coactivator 4, ferritin heavy chain 1, ferroportin 1, iron-responsive element-binding protein 2, and heme oxygenase 1. Moreover, ferrostatin-1 and deferoxamine mesylate partially rescued RTS-induced cytotoxicity and alleviated oxidative damage and iron overload. These results indicate that RTS induces ferroptosis-associated cell death in NB4 cells by disrupting iron homeostasis and inhibiting the SLC7A11/GPX4 axis, supporting further investigation of RTS as a modernized arsenic-based anti-leukemic formulation.

PMID 42716792
阅读全文 →
PubMedCell biochemistry and function2026-09-09

Melatonin Protects BEAS-2B Cells Against Hypoxia/Reoxygenation-Induced Injury By Reducing MLKL Levels, Suppressing Oxidative Stress and Preserving Mitochondrial Function.

Yilmaz Zehra Z, Tas Askin A, Oz Ozlem O, Koyuncu Ismail I et al.

Necroptosis has been demonstrated to play a role in the process of lung ischemia-reperfusion injury (LIRI) in a variety of clinical conditions, including cardiopulmonary bypass and pulmonary embolism. Melatonin has been reported to exert a protective role by reducing oxidative stress and acute inflammatory reactions in LIRI. However, the effect of melatonin on necroptosis in LIRI remains unclear. The aim of this study was to investigate whether the protective effects of melatonin against H/R-induced injury are associated with modulation of necroptosis and related changes in mitochondrial function and oxidative stress. The cells were exposed to H/R (16/4 h) or normoxia, in the absence or presence of 2.5 µM melatonin. Cell viability was determined by the MTT method, while morphological changes in BEAS-2B cells resulting from H/R exposure were evaluated by fluorescence microscopy using acridine orange/ethidium bromide (AO/EtBr) staining. Mechanistic analyses, including flow cytometry-based cell cycle assessment, apoptosis detection (Annexin V-FITC), mitochondrial membrane potential evaluation (JC-1), and reactive oxygen species (ROS) measurements, were performed on BEAS-2B cells. The level of the mixed lineage kinase domain-like pseudokinase (MLKL), a key component of the necroptosis complex, was also quantified using an enzyme-linked immunosorbent assay. In addition, the ATP, pH, and lactate levels were determined. The findings indicated that melatonin treatment reduced the H/R-induced increase in the percentage of necrotic cells and increased the percentage of viable cells (p < 0.05). In addition, melatonin treatment reduced the increase in MLKL, ROS, and lactate levels, preserved mitochondrial membrane integrity, and increased intracellular ATP levels in BEAS-2B cells exposed to H/R (p < 0.05). In conclusion, this study suggests that melatonin protects BEAS-2B cells against H/R-induced injury, and that this protective effect may be associated with reduced oxidative stress, preservation of mitochondrial function, and suppression of necroptosis-related signaling.

PMID 42714108
阅读全文 →
PubMedMicrobiology spectrum2026-09-09

Genomic characterization of efflux pumps and putative small multidrug resistance (SMR)-like transporters in disinfectant-tolerant coagulase-negative staphylococci from a Vietnamese hospital.

Hung Dao Hai DH, Hien Le Phung LP, Oanh Pham Kieu PK, Huyen Ngo Thi Thanh NTT et al.

Coagulase-negative staphylococci (CoNS) are common inhabitants of healthcare environments and can serve as reservoirs of antimicrobial resistance determinants. However, the relationship among disinfectant tolerance, efflux-associated phenotypes, and multidrug resistance in environmental CoNS remains incompletely defined. Here, 51 staphylococcal isolates were recovered from high-touch hospital surfaces in Hanoi, Vietnam, and 14 isolates showed elevated MICs to at least one disinfectant, including benzalkonium chloride, chlorhexidine gluconate, or hydrogen peroxide, relative to Staphylococcus aureus ATCC 25923. These isolates also displayed multidrug-resistant phenotypes. Moreover, ethidium bromide accumulation assays revealed a clear efflux-associated phenotype, and representative isolates exhibited biofilm-forming ability. Whole-genome sequencing of three representative isolates reclassified SDH.B1 and SDH.B3 as Staphylococcus nepalensis-a CoNS species rarely documented in hospital AMR surveillance-and confirmed SDH.B7 as Staphylococcus haemolyticus. To our knowledge, this is among the first reports of S. nepalensis carrying mecA together with the disinfectant efflux gene qacG, and a set of putative small multidrug resistance (SMR)-like transporters in a hospital environment from Southeast Asia. In addition, six putative SMR-like proteins were identified. Phylogenetic and structural analyses suggested relatedness to YkkC/YkkD-like systems, although their transport activity remains to be experimentally verified. These findings identify environmental CoNS as reservoirs of disinfectant tolerance and multidrug resistance in hospital settings and provide a basis for future functional investigation of putative SMR-like transporters.IMPORTANCEHospital environmental CoNS are often dismissed as low-priority contaminants, yet they may persist under disinfectant pressure and carry clinically relevant resistance determinants. Here, disinfectant-tolerant CoNS recovered from a Vietnamese hospital combined multidrug resistance, efflux-associated phenotypes, and biofilm-related traits. Genome analysis further revealed known qac genes and six putative SMR-like proteins that merit functional testing. These findings support inclusion of environmental CoNS in infection-prevention surveillance and disinfectant stewardship programs.

PMID 42714170
阅读全文 →
PubMedChinese journal of cancer research = Chung-kuo yen cheng yen chiu2026-09-09

Decoding age-stratified clinical and molecular heterogeneity in male breast cancer through multiomic profiling.

Gao Zhishuang Z, Wang Zehao Z, Zhou Yue Y, Chen Xiaoting X et al.

Age-associated molecular heterogeneity is well described in female breast cancer but remains insufficiently characterized in male breast cancer (MBC). We profiled age-stratified clinical and molecular differences between younger (≤55 years) male breast cancer (YMBC) and older (>55 years) male breast cancer (OMBC). We retrospectively analyzed 347 patients with MBC diagnosed at Fudan University Shanghai Cancer Center by integrating clinicopathological data, RNA sequencing, and whole-exome sequencing (WES). Survival, differential expression, and mutational signature analyses were performed. Tumor microenvironment features were inferred using xCell and ESTIMATE, and weighted gene co-expression network analysis (WGCNA) was conducted to identify age-associated co-expression modules. Candidate therapeutics were prioritized using the Genomics of Drug Sensitivity in Cancer (GDSC) resource and evaluated using patient-derived organoids (PDOs). Compared with OMBC, YMBC more frequently had human epidermal growth factor receptor 2 (HER2)-positive status (14.91% vs. 4.02%) and triple-negative tumors (4.92% vs. 1.78%), and had worse 5-year recurrence-free survival (hazard ratio=2.19, P=0.018). Transcriptomic analyses indicated enrichment of neural-related programs and reduced immune-related signaling in YMBC, and xCell/ESTIMATE supported lower immune infiltration. Consistently, WGCNA identified age-associated modules linking neural-related programs with reduced immune infiltration. Immunohistochemistry supported increased perineural invasion and lower CD8+ T cell infiltration in YMBC. GDSC-guided prioritization with PDO testing nominated sepantronium bromide (YM155) as a candidate vulnerability in YMBC. WES showed a higher NBPF10 mutation frequency in YMBC (54.5% vs. 14.3%, P<0.05). Integrated multi-omics profiling revealed age-stratified clinical and molecular heterogeneity in MBC. YMBC patients demonstrated inferior recurrence-free survival, neural signaling enrichment, an immune-cold microenvironment, and enriched NBPF10 mutations. These findings support age as a meaningful stratification variable in MBC risk assessment and treatment planning, and highlight the need for caution when considering treatment de-escalation in younger patients, while nominating YM155 as a candidate agent for prospective evaluation.

PMID 42712807
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多salbutamol + ipratropium bromide